Literature DB >> 20433886

Polymorphisms in the 2q33 and 3q21 chromosome regions including T-cell coreceptor and ligand genes may influence susceptibility to pemphigus foliaceus.

Ricardo Dalla-Costa1, Márcia Regina Pincerati, Márcia Holsbach Beltrame, Danielle Malheiros, Maria Luiza Petzl-Erler.   

Abstract

Signaling through antigen presenting cells is required to activate T lymphocytes. The antigen-specific signal is given by interaction of the T-cell receptor (TCR) with the major histocompatibility complex (MHC)/peptide complex. Also essential for activation is the interaction of the coreceptor CD28 with ligands of the B7 family (CD80 and CD86) on antigen presenting cells. Coreceptor CTLA-4 is a negative regulator and binds the same B7 isoforms, contributing to immunologic homeostasis and peripheral tolerance. CD28 and CTLA4 are homologous and closely linked genes in 2q33, as are CD80 and CD86 in the 3q21 chromosomal region. Pemphigus foliaceus (PF) is a multifactorial autoimmune blistering disease characterized by keratinocyte detachment and by autoantibodies against desmoglein 1, a desmosomal protein. To investigate the involvement of CD28, CTLA4, CD80, and CD86 genes in PF pathogenesis, 18 polymorphisms in 2q33 and 3q21 chromosomal regions were analyzed in 269 patients and 395 controls subdivided according to predominant ancestry in Euro-Brazilian and Afro-Brazilian individuals. Associations were found with CD86 1057G>A, CTLA4-1722T>C, CTLA4-318C>T, CTLA4(AT)n, CD28(CAA)n, and D2S72(CA)n. There is no evidence of gene-gene interactions. We conclude that polymorphisms in the 2q33 and 3q21 chromosomal regions may influence PF disease susceptibility, most likely affecting CTLA4 and possibly inducible T-cell costimulator, (ICOS) expression, and also CD86 function. Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433886     DOI: 10.1016/j.humimm.2010.04.001

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Screening the full leucocyte receptor complex genomic region revealed associations with pemphigus that might be explained by gene regulation.

Authors:  Ticiana Della Justina Farias; Danillo G Augusto; Rodrigo Coutinho de Almeida; Danielle Malheiros; Maria Luiza Petzl-Erler
Journal:  Immunology       Date:  2018-10-11       Impact factor: 7.397

2.  Sparking Fire Under the Skin? Answers From the Association of Complement Genes With Pemphigus Foliaceus.

Authors:  Valéria Bumiller-Bini; Gabriel Adelman Cipolla; Rodrigo Coutinho de Almeida; Maria Luiza Petzl-Erler; Danillo Gardenal Augusto; Angelica Beate Winter Boldt
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

3.  HLA Class III: A susceptibility region to systemic lupus erythematosus in Tunisian population.

Authors:  Hend Hachicha; Nadia Mahfoudh; Hajer Fourati; Nesrine Elloumi; Sameh Marzouk; Sawsan Feki; Raouia Fakhfakh; Faten Frikha; Abir Ayadi; Amira Maatoug; Lilia Gaddour; Feiza Hakim; Zouheir Bahloul; Hafedh Makni; Hatem Masmoudi; Arwa Kammoun
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

Review 4.  Autoimmune Pemphigus: Latest Advances and Emerging Therapies.

Authors:  Yen Loo Lim; Gerome Bohelay; Sho Hanakawa; Philippe Musette; Baptiste Janela
Journal:  Front Mol Biosci       Date:  2022-02-04

Review 5.  Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.

Authors:  Adrian Chye; India Allen; Megan Barnet; Deborah L Burnett
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

6.  Chromosome 2q33genetic polymorphisms in Tunisian endemic pemphigus foliaceus.

Authors:  Olfa Abida; Emna Bahloul; Mariem Ben Jmaa; Khadija Sellami; Ferjani Zouidi; Raouia Fakhfakh; Nadia Mahfoudh; Hamida Turki; Hatem Masmoudi
Journal:  Mol Genet Genomic Med       Date:  2020-09-01       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.